Inadequate Response to Antidepressant Treatment in Major Depressive Disorder

George I. Papakostas, MD
W. Clay Jackson, MD
Roueen Rafeyan, MD
Madhukar H. Trivedi, MD

This Commentary presents highlights of the roundtable meeting “Inadequate Response to Antidepressant Treatment in Major Depressive Disorder,” which was held October 5, 2019, in San Diego, California. The panel of experts presented on and then discussed topics relevant to inadequate response, including how to determine where patients are on the response continuum and how to manage patients with inadequate response. Their presentations are summarized here. Visit Psychiatrist.com/IR to access the free eReports, including video clips from the meeting, to learn more about inadequate response to antidepressants in MDD.

Many patients treated for major depressive disorder (MDD) experience relatively modest rates of response and remission despite the large number of antidepressant (AD) medications available. Side effects can hinder treatment adherence, while residual symptoms can contribute to increased functional impairment, morbidity, and mortality. Clinicians should feel a sense of urgency to help patients who have inadequate response to initial treatment, especially since people with MDD have reduced life expectancy compared to those without MDD. Lack of remission is also associated with an increased risk of relapse and recurrence, higher use of health care resources, higher rates of chronicity, and decreased quality of life. Therefore, distinguishing response from remission has clinical significance and requires systematic monitoring of the presence and severity of depressive symptoms.

Defining inadequate response. Nonresponders are patients who show little to no improvement in depressive symptoms, typically less than 25% improvement on a depression rating scale. Partial responders, or patients with inadequate response, show some improvement in symptoms, between 25% and 49% on a rating scale, but still have troublesome symptoms that negatively impact their functioning. Responders are patients with 50% improvement or more, but they still have not achieved remission and may require treatment for residual symptoms. Patients who achieve remission are virtually symptom-free and can return to normal functioning.

In contrast to patients with inadequate response, patients with treatment-resistant depression (TRD) are characterized by a longer treatment history during the current episode, such as 2 or more treatment trial failures, and often exhibit a sense of discouragement or hopelessness.

Recognizing residual symptoms. Patients who achieve response and even remission often struggle with residual symptoms, including low mood, anxiety, irritability, and guilt. In terms of functional impact, patients may show lack of interest and work impairment. Cognition can be an issue, including impaired memory and increased cognitive reactivity. Common somatic symptoms include reduced libido, insomnia, fatigue, and pain.

Contributing factors. Multiple factors may contribute to failure of initial AD therapy, including an inadequate AD dose or trial duration, treatment nonadherence, and misdiagnosis. Poor adherence to prescribed treatment along with poor tolerability are factors that often contribute to treatment nonresponse in MDD. Clinicians can improve adherence by providing patient education and consistent follow-up to strengthen the therapeutic alliance. What patients think about treatment also matters, because preference predicts both therapeutic alliance and adherence in treatment for MDD. Finally, clinicians must be aware that poor response may be the result of a misdiagnosis of bipolar disorder or MDD with mixed features.

Implementing Measurement-Based Care to Determine and Treat Inadequate Response

Next, Dr Trivedi outlined the importance of using measurement-based care (MBC) to improve outcomes for patients with inadequate response. Response is generally defined as a 50% decrease in symptoms from baseline on a depression severity rating scale. Rating scales are used to measure this change because...
Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies

Dr. Rafeyan reviewed the evidence for current treatment strategies for inadequate response in MDD. These strategies include switching ADs, combining ADs, optimizing the AD dose, and augmenting the current AD.12,13 In many cases, augmentation strategies can accelerate response to AD therapy and alleviate troublesome symptoms faster than several different AD monotherapy trials.

Among adjunctive treatments used on an off-label basis in MDD, the trials of augmentation of ADs with buspirone and methylphenidate did not show statistical significance,12 but modafinil may help patients experiencing sleepiness or fatigue.14 Positive placebo-controlled studies of lithium12,15 and thyroid7,16 augmentation, mostly with tricyclic ADs, were identified, although results are inconsistent.

Atypical antipsychotics show significantly higher response rates compared to AD alone, and augmentation can have a significant effect on symptoms and improvement.12,13 The 4 atypical antipsychotics to receive US Food and Drug Administration (FDA) approval as augmentation for the treatment of MDD are aripiprazole, quetiapine extended release, olanzapine plus fluoxetine combination, and brexipiprazole.17 Other atypical antipsychotics have had mixed results in MDD and remain off-label for their use as augmenting agents to AD treatment.17 Clinicians must monitor side effects and provide education to patients about the benefits and risks of these agents in order to improve adherence.

Overcoming Challenges to Treat Inadequate Response in Major Depressive Disorder

Dr. Papakostas summarized key points from the meeting and addressed common challenges in the treatment of inadequate response. He noted a broadening of the types of treatments available for MDD. Traditional AD monotherapies are often used sequentially, but the STAR*D study showed that the outcomes for more than 2 subsequent AD trials are diminished.18,19 For patients with inadequate response, adjunctive treatment strategies include atypical antipsychotics, lithium, and thyroid hormone.20 For patients with TRD, treatments include neurostimulation therapies (eg, electroconvulsive therapy, transcranial magnetic stimulation) and esketamine.21–23

Although the atypical antipsychotics were developed 10 years ago, they may be underutilized, with many clinicians more likely to switch agents than to augment.24 Meta-analyses show that adjunctive antipsychotics are significantly more effective than placebo for response and remission, even with no response to initial AD.25 However, clinicians must monitor side effects.13 Other adjunctive strategies for patients with inadequate response to AD treatment include L-methylfolate and SAMe,26,27 exercise,28 and psychotherapy.20

The challenge for the clinician is figuring out which of these available treatments to use based on their patients’ response to current and past therapies, symptom severity, and preference. Current guidelines offer a big-picture view of treating partial response and nonresponse using strategies such as optimizing the dose, switching to a different AD, changing to or augmenting with psychotherapy, adding adjunctive therapy, or considering neurostimulation or esketamine.20,29

While guidelines can provide a good synthesis of the evidence of the literature, they do not have the same level of detail as treatment algorithms, nor do they capture the differences between inadequate response and TRD or take into account new and emerging treatments. Clinicians can keep up with the literature on novel treatments through other sources, such as peer-reviewed journals and CME programs, which can be updated more frequently than treatment guidelines.

Conclusion

Clinicians face many challenges in the treatment of patients with MDD who experience inadequate response to ADs, but MBC can improve outcomes through the use of regular assessment, patient education, and critical decision points. Antidepressant treatment options are more varied than ever, requiring clinicians to keep up with the evidence for new and emerging treatments. Evidence suggests that adjunctive therapies, such as the FDA-approved atypical antipsychotics, are more efficacious than switching ADs when the initial treatment is well tolerated but is not significantly improving symptoms. Clinicians should also be familiar with the available options for psychotherapy, supplements, and exercise for patients who prefer alternative therapies.


